(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 22 February 2001 (22.02.2001)

PCT

(10) International Publication Number **WO 01/12579 A2**

(51) International Patent Classification7: A61K 31/09, A61P 35/00, C07F 9/12

(21) International Application Number: PCT/GB00/03067

(22) International Filing Date: 9 August 2000 (09.08.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

9918912.8

12 August 1999 (12.08.1999)

(71) Applicant (for all designated States except US): AN-GIOGENE PHARMACEUTICALS LTD. [GB/GB]; 14 Plowden Park, Aston Rowant, Watlington, Oxfordshire OX9 5S (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): DAVIS, Peter, David [GB/GB]; 10 Aston Park, Aston Rowant, Watlington OX9 5SX (GB).

C07C 43/23, (74) Agents: BAILLIE, Iain, C. et al.; Languer Parry, 52-54 High Holborn, London WC1V 6RR (GB).

> (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR. HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

> (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published:


Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



i





(57) Abstract: A group of novel cis-stilbenes as disclosed of formula (1) wherein: R¹, R² and R³ are each independently alkyl, R⁴ is alkyl, haloalkyl, alkenyl, alkynyl, alkylthio, alkylsulphinyl, alkylsulphonyl or halo, R5 is hydrogen, alkoxy, alkyl, alkylthio, hydroxy or halo, or a pharmaceutically acceptable salt thereof or a prodrug such as a phosphate ester. These compounds have vascular damaging activity and are therefore potentially of value in treatment of diseases where reversal of neovascularisation may have therapeutic benefit.